Nexavar with dacarbazine improves survival in advanced melanoma « Kinase News

Blogroll
Tags
AstraZeneca aurora Avastin bayer Bcr-Abl bevacizumab BMS c-kit cetuximab EGFR ErbB-2 ErbB2 erbitux Exelixis Genentech GlaxoSmithKline Gleevec GSK HER1 HER2 IGF-1R Imatinib ImClone JAK2 kinase Merck-Serono Met mTOR multikinase Nexavar Novartis onyx PDGF Pfizer phase I Phase II phase iii PI3K Preclinical regulatory Research Roche sorafenib VEGF VEGFR2
Providing a resource for information on kinase inhibitors

Nexavar with dacarbazine improves survival in advanced melanoma

Posted on May 7, 2008 by crimsoncanary

Results from a Phase II study show Nexavar (sorafenib), in combination with dacarbazine, improves progression-free survival (PFS) in patients with advanced melanoma

Filed under: kinase | Tagged: bayer, multikinase, Nexavar, onyx, sorafenib

« Crelux and ProQinase collaborate to provide off-the-shelf crystal-grade protein kinase portfolio ACT Biotech acquire kinase inhibitors from Bayer »

Leave a Reply